153 related articles for article (PubMed ID: 18191981)
1. West Nile virus is neutralized by HOCl-modified human serum albumin that binds to domain III of the viral envelope protein E.
Vossmann M; Kirst M; Ludolfs D; Schreiber M
Virology; 2008 Apr; 373(2):322-8. PubMed ID: 18191981
[TBL] [Abstract][Full Text] [Related]
2. Live measles vaccine expressing the secreted form of the West Nile virus envelope glycoprotein protects against West Nile virus encephalitis.
Desprès P; Combredet C; Frenkiel MP; Lorin C; Brahic M; Tangy F
J Infect Dis; 2005 Jan; 191(2):207-14. PubMed ID: 15609230
[TBL] [Abstract][Full Text] [Related]
3. Common E protein determinants for attenuation of glycosaminoglycan-binding variants of Japanese encephalitis and West Nile viruses.
Lee E; Hall RA; Lobigs M
J Virol; 2004 Aug; 78(15):8271-80. PubMed ID: 15254199
[TBL] [Abstract][Full Text] [Related]
4. Antiviral peptides targeting the west nile virus envelope protein.
Bai F; Town T; Pradhan D; Cox J; Ashish ; Ledizet M; Anderson JF; Flavell RA; Krueger JK; Koski RA; Fikrig E
J Virol; 2007 Feb; 81(4):2047-55. PubMed ID: 17151121
[TBL] [Abstract][Full Text] [Related]
5. Adaptation of West Nile virus replicons to cells in culture and use of replicon-bearing cells to probe antiviral action.
Rossi SL; Zhao Q; O'Donnell VK; Mason PW
Virology; 2005 Jan; 331(2):457-70. PubMed ID: 15629788
[TBL] [Abstract][Full Text] [Related]
6. Recombinant West Nile virus envelope protein E and domain III expressed in insect larvae protects mice against West Nile disease.
Alonso-Padilla J; de Oya NJ; Blázquez AB; Escribano-Romero E; Escribano JM; Saiz JC
Vaccine; 2011 Feb; 29(9):1830-5. PubMed ID: 21211580
[TBL] [Abstract][Full Text] [Related]
7. Expression of vector-based small interfering RNA against West Nile virus effectively inhibits virus replication.
Ong SP; Choo BG; Chu JJ; Ng ML
Antiviral Res; 2006 Dec; 72(3):216-23. PubMed ID: 16870272
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of apoptosis prevents West Nile virus induced cell death.
Kleinschmidt MC; Michaelis M; Ogbomo H; Doerr HW; Cinatl J
BMC Microbiol; 2007 May; 7():49. PubMed ID: 17535425
[TBL] [Abstract][Full Text] [Related]
9. Antibodies targeting linear determinants of the envelope protein protect mice against West Nile virus.
Ledizet M; Kar K; Foellmer HG; Bonafé N; Anthony KG; Gould LH; Bushmich SL; Fikrig E; Koski RA
J Infect Dis; 2007 Dec; 196(12):1741-8. PubMed ID: 18190253
[TBL] [Abstract][Full Text] [Related]
10. Effective siRNA targeting of the 3' untranslated region of the West Nile virus genome.
Anthony KG; Bai F; Krishnan MN; Fikrig E; Koski RA
Antiviral Res; 2009 Jun; 82(3):166-8. PubMed ID: 19135091
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of West Nile virus entry by using a recombinant domain III from the envelope glycoprotein.
Chu JJH; Rajamanonmani R; Li J; Bhuvanakantham R; Lescar J; Ng ML
J Gen Virol; 2005 Feb; 86(Pt 2):405-412. PubMed ID: 15659760
[TBL] [Abstract][Full Text] [Related]
12. RNA elements within the 5' untranslated region of the West Nile virus genome are critical for RNA synthesis and virus replication.
Li XF; Jiang T; Yu XD; Deng YQ; Zhao H; Zhu QY; Qin ED; Qin CF
J Gen Virol; 2010 May; 91(Pt 5):1218-23. PubMed ID: 20016034
[TBL] [Abstract][Full Text] [Related]
13. A West Nile virus recombinant protein vaccine that coactivates innate and adaptive immunity.
McDonald WF; Huleatt JW; Foellmer HG; Hewitt D; Tang J; Desai P; Price A; Jacobs A; Takahashi VN; Huang Y; Nakaar V; Alexopoulou L; Fikrig E; Powell TJ
J Infect Dis; 2007 Jun; 195(11):1607-17. PubMed ID: 17471430
[TBL] [Abstract][Full Text] [Related]
14. Differential expression of domain III neutralizing epitopes on the envelope proteins of West Nile virus strains.
Li L; Barrett AD; Beasley DW
Virology; 2005 Apr; 335(1):99-105. PubMed ID: 15823609
[TBL] [Abstract][Full Text] [Related]
15. In silico screening of small molecule libraries using the dengue virus envelope E protein has identified compounds with antiviral activity against multiple flaviviruses.
Kampmann T; Yennamalli R; Campbell P; Stoermer MJ; Fairlie DP; Kobe B; Young PR
Antiviral Res; 2009 Dec; 84(3):234-41. PubMed ID: 19781577
[TBL] [Abstract][Full Text] [Related]
16. Ribavirin inhibits West Nile virus replication and cytopathic effect in neural cells.
Jordan I; Briese T; Fischer N; Lau JY; Lipkin WI
J Infect Dis; 2000 Oct; 182(4):1214-7. PubMed ID: 10979920
[TBL] [Abstract][Full Text] [Related]
17. A single amino acid substitution in the central portion of the West Nile virus NS4B protein confers a highly attenuated phenotype in mice.
Wicker JA; Whiteman MC; Beasley DW; Davis CT; Zhang S; Schneider BS; Higgs S; Kinney RM; Barrett AD
Virology; 2006 Jun; 349(2):245-53. PubMed ID: 16624366
[TBL] [Abstract][Full Text] [Related]
18. A West Nile virus mutant with increased resistance to acid-induced inactivation.
Martín-Acebes MA; Saiz JC
J Gen Virol; 2011 Apr; 92(Pt 4):831-40. PubMed ID: 21228127
[TBL] [Abstract][Full Text] [Related]
19. DC-SIGN enhances infection of cells with glycosylated West Nile virus in vitro and virus replication in human dendritic cells induces production of IFN-alpha and TNF-alpha.
Martina BE; Koraka P; van den Doel P; Rimmelzwaan GF; Haagmans BL; Osterhaus AD
Virus Res; 2008 Jul; 135(1):64-71. PubMed ID: 18405996
[TBL] [Abstract][Full Text] [Related]
20. Error-prone replication of West Nile virus caused by ribavirin.
Day CW; Smee DF; Julander JG; Yamshchikov VF; Sidwell RW; Morrey JD
Antiviral Res; 2005 Jul; 67(1):38-45. PubMed ID: 15919121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
